A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk managemen...

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs

S Mozaffari, S Nikfar, M Abdollahi - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Irritable bowel syndrome (IBS) has a significant impact on society and quality of
life. Current treatments are ineffective, and new investigational drugs are necessary. Areas …
被引用次数：1 相关文章 所有 3 个版本

Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?

S Mozaffari, S Nikfar, M Abdollahi - Expert Opinion on Drug …, 2024 - Taylor & Francis
Introduction Irritable bowel syndrome (IBS), which presents a significant healthcare and
socioeconomic burden, is one of the main issues in the field of therapy. Hence, it is …
相关文章 所有 3 个版本

Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review

A Deljavan Ghodrati, T Comoglu - Archiv der Pharmazie, 2024 - Wiley Online Library
Rifaximin, a broad‐spectrum antibiotic, boasts a unique chemical composition and
pharmacokinetic profile, rendering it highly effective in treating irritable bowel syndrome …
相关文章 所有 3 个版本

Algorithms or biomarkers in patients with lower DGBI?

M Camilleri, DY Yang - Neurogastroenterology & Motility, 2024 - Wiley Online Library
Background Several organizations have proposed guidelines or clinical decision tools for
the management of patients with disorders of gut‐brain interactions (DGBI) affecting the …
相关文章 所有 3 个版本